Australia · Delayed Price · Currency is AUD Ramsay Health Care Earnings Call Transcripts
Fiscal Year 2026
-
Underlying EBIT and NPAT grew 7.3% and 8.1% year-over-year, led by strong Australian performance and disciplined capital allocation. Guidance points to continued EBIT growth in Australia, ongoing Elysium turnaround, and reduced CapEx, with the Ramsay Santé demerger expected by December 2026.
-
A strategic review has led to the decision to distribute Ramsay Santé shares to shareholders, simplifying the group and enabling each business to focus on its core markets. The process will be executed via a scheme of arrangement, targeting completion in Q4 2026, with minimal operational disruption expected.
Fiscal Year 2025
-
The meeting highlighted a modest profit increase, a fully franked dividend, and a strategic focus on transforming the Australian business, capital discipline, and cultural innovation. Shareholders supported all board and remuneration resolutions, while management addressed concerns over offshore investments and operational challenges.
-
FY 2025 saw modest profit growth excluding non-recurring items, with strong Australian and U.K. hospital performance offset by challenges in Elysium and Ramsay Santé. FY 2026 guidance anticipates EBIT growth in Australia, continued operational improvements, and disciplined capital allocation.
-
Net loss was AUD 104.9 million due to significant non-recurring items, but underlying NPAT rose 10.7% on strong Australian and U.K. hospital performance. Strategic reviews and transformation efforts are underway, with capital discipline and cost management as key priorities.
Fiscal Year 2024
-
The AGM addressed leadership transition, financial results, and ongoing transformation programs to improve margins and shareholder returns. Shareholders raised concerns about share price, global strategy, staff conditions, and clinical safety, with management emphasizing continued investment in people, technology, and sustainability.
-
Leading positions in key therapeutic areas and high-growth regions, supported by a robust transformation program, are driving operational efficiency, margin improvement, and sustainable growth. Digital and data investments, procurement optimization, and targeted expansion underpin a positive financial outlook.
-
Group revenue from patient activity grew 7.3% in FY 2024, with EBIT up 6.1% and NPAT up 24.5% (constant currency, excluding non-recurring items). Activity and profit are expected to grow in FY 2025, though at a slower rate, with margin pressure from wage inflation and tariff indexation lag.